Liver Imaging Reporting and Data System Version 2018: Impact on Categorization and Hepatocellular Carcinoma Staging

Victoria Chernyak, Milana Flusberg, Jesse Berman, Kate C. Fruitman, Mariya Kobi, Kathryn J. Fowler, Claude B. Sirlin – 25 July 2019 – The purpose of this study was to assess the concordance in categorization and radiologic T staging using Liver Imaging Reporting and Data System (LI‐RADS, LR) version 2017 (v2017), version 2018 (v2018), and the Organ Procurement and Transplantation Network (OPTN) criteria. All magnetic resonance imaging and computed tomography reports using a standardized LI‐RADS macro between April 2015 and March 2018 were identified retrospectively.

Profiling Gene Programs in the Blood During Liver Regeneration in Living Liver Donors

Michael C. Lawrence, Carly M. Darden, Srividya Vasu, Kenjiro Kumano, Jinghua Gu, Xuan Wang, Jinyan Chan, Zhaohui Xu, Benjamin F. Lemoine, Phuong Nguyen, Cynthia Smitherman, Bashoo Naziruddin, Giuliano Testa – 24 July 2019 – The human liver’s capacity to rapidly regenerate to a full‐sized functional organ after resection has allowed successful outcomes for living donor liver transplantation (LDLT) procedures. However, the ability to detect and track physiological changes occurring during liver regeneration after resection and throughout the restoration process is still lacking.

LiverLearning®: 2019 Webinar: Challenges in Antiviral Therapy for Hepatitis C

Management of HCV after therapy has complexity if patients continue to engage in high risk activities, are at risk for advanced liver disease progression or have failed first line therapy. In addition, these complexities are especially important to consider as HCV therapy moves outside of subspecialty care. We will utilize a live webinar format that will be recorded for on-demand viewing on Liver Learning ® .Stuart C. Gordon Dr. Gordon is a Professor of Medicine at Wayne State University School of Medicine and Director, Division of Hepatology, at Henry Ford Hospital.

A Therapeutic Silencing RNA Targeting Hepatocyte TAZ Prevents and Reverses Fibrosis in Nonalcoholic Steatohepatitis in Mice

Xiaobo Wang, Mark R. Sommerfeld, Kerstin Jahn‐Hofmann, Bishuang Cai, Aveline Filliol, Helen E. Remotti, Robert F. Schwabe, Aimo Kannt, Ira Tabas – 23 July 2019 – Nonalcoholic steatohepatitis (NASH) is emerging as a major public health issue and is associated with significant liver‐related morbidity and mortality. At present, there are no approved drug therapies for NASH.

Subscribe to